MARCOMIGNI, Luca
 Distribuzione geografica
Continente #
NA - Nord America 59
AS - Asia 54
EU - Europa 42
Totale 155
Nazione #
US - Stati Uniti d'America 59
VN - Vietnam 19
IE - Irlanda 18
SG - Singapore 15
HK - Hong Kong 12
IT - Italia 8
CN - Cina 6
FI - Finlandia 4
DE - Germania 3
FR - Francia 3
RU - Federazione Russa 3
AT - Austria 1
KR - Corea 1
NL - Olanda 1
UA - Ucraina 1
UZ - Uzbekistan 1
Totale 155
Città #
Dong Ket 19
Dublin 18
Hong Kong 12
Singapore 12
Chandler 11
Boardman 10
San Mateo 5
Santa Clara 5
Altamura 4
Beijing 3
Lawrence 3
Medford 3
Princeton 3
Helsinki 2
Munich 2
Redwood City 2
Saint Petersburg 2
Wilmington 2
Amelia 1
Amsterdam 1
Aprilia 1
Frankfurt am Main 1
Guangzhou 1
Seoul 1
Vienna 1
Totale 125
Nome #
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 73
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 40
Diagnosis and therapeutic management of parathyroid cancer, starting from the description of a clinical case 23
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 13
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 12
Totale 161
Categoria #
all - tutte 1.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.047


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205 0 0 0 0 0 1 0 1 0 3 0 0
2020/202125 0 0 0 0 6 0 0 0 0 0 0 19
2021/202214 0 3 0 0 0 0 0 6 0 0 2 3
2022/202347 3 9 2 1 4 3 0 1 22 0 2 0
2023/202439 1 4 1 0 0 1 6 0 8 0 9 9
2024/202523 2 7 5 1 8 0 0 0 0 0 0 0
Totale 161